MCID: 47X002
MIFTS: 48

47,xyy

Categories: Fetal diseases, Mental diseases, Muscle diseases, Rare diseases

Aliases & Classifications for 47,xyy

MalaCards integrated aliases for 47,xyy:

Name: 47,xyy 74
Xyy Syndrome 74 20 43 58
Double Y Syndrome 20 58 29
47,xyy Syndrome 20 43 58
47, Xyy Syndrome 20 71
Xyy Karyotype 20 43
Yy Syndrome 20 43
Y Disomy 20 58
Camptodactyly-Arthropathy-Coxa Vara-Pericarditis Syndrome 71
Jacob's Syndrome 43
Jacobs Syndrome 20
Disomy Y 20
Double Y 20

Characteristics:

Orphanet epidemiological data:

58
47,xyy syndrome
Inheritance: Not applicable; Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Developmental anomalies during embryogenesis


Summaries for 47,xyy

MedlinePlus Genetics : 43 47,XYY syndrome is characterized by an extra copy of the Y chromosome in each of a male's cells. Although many males with this condition are taller than average, the chromosomal change sometimes causes no unusual physical features. Most males with 47,XYY syndrome have normal production of the male sex hormone testosterone and normal sexual development, and they are usually able to father children.47,XYY syndrome is associated with an increased risk of learning disabilities and delayed development of speech and language skills. Affected boys can have delayed development of motor skills (such as sitting and walking) or weak muscle tone (hypotonia). Other signs and symptoms of this condition include hand tremors or other involuntary movements (motor tics), seizures, and asthma. Males with 47,XYY syndrome have an increased risk of behavioral, social, and emotional difficulties compared with their unaffected peers. These problems include attention-deficit/hyperactivity disorder (ADHD); depression; anxiety; and autism spectrum disorder, which is a group of developmental conditions that affect communication and social interaction.Physical features related to 47,XYY syndrome can include increased belly fat, a large head (macrocephaly), unusually large teeth (macrodontia), flat feet (pes planus), fifth fingers that curve inward (clinodactyly), widely spaced eyes (ocular hypertelorism), and abnormal side-to-side curvature of the spine (scoliosis). These characteristics vary widely among affected boys and men.

MalaCards based summary : 47,xyy, also known as xyy syndrome, is related to turner syndrome and camptodactyly-arthropathy-coxa vara-pericarditis syndrome. An important gene associated with 47,xyy is IGFBP3 (Insulin Like Growth Factor Binding Protein 3). The drugs Ethanol and Labetalol have been mentioned in the context of this disorder. Affiliated tissues include prostate, myeloid and bone marrow, and related phenotypes are delayed speech and language development and low-set ears

GARD : 20 47, XYY syndrome is a syndrome (group of signs and symptoms) that affects males. For some males with this syndrome, signs and symptoms are barely noticeable. For others, signs and symptoms may include learning disabilities, speech delay, low muscle tone (hypotonia), and being taller than expected. 47, XYY syndrome is caused by having an extra copy of the Y chromosome in every cell of the body. The syndrome is usually not inherited. Diagnosis can be made based on prenatal tests, or it may occur during childhood or adulthood if a male has signs or symptoms of the disease. Management may include special education as well as intervention or therapies for developmental delays.

Wikipedia : 74 XYY syndrome is a genetic condition in which a male has an extra Y chromosome. There are usually few... more...

Related Diseases for 47,xyy

Diseases related to 47,xyy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 139)
# Related Disease Score Top Affiliating Genes
1 turner syndrome 29.3 SRY IGFBP3
2 camptodactyly-arthropathy-coxa vara-pericarditis syndrome 11.4
3 numeric sex chromosome variations 11.2
4 gonadal dysgenesis 10.4
5 infertility 10.4
6 48,xyyy 10.4
7 azoospermia 10.4
8 autism spectrum disorder 10.3
9 cryptorchidism, unilateral or bilateral 10.2
10 tooth size 10.2
11 gonadoblastoma 10.2
12 hypogonadotropic hypogonadism 10.2
13 mixed gonadal dysgenesis 10.2
14 chromosomal triplication 10.2
15 attention deficit-hyperactivity disorder 10.2
16 prader-willi syndrome 10.2
17 male infertility 10.2
18 hypogonadism 10.2
19 hypotonia 10.2
20 tremor 10.2
21 hair whorl 10.1
22 hypertelorism 10.1
23 down syndrome 10.1
24 taurodontism 10.1
25 fragile x syndrome 10.1
26 hypospadias 10.1
27 heart disease 10.1
28 synostosis 10.1
29 oligospermia 10.1
30 cystic lymphangioma 10.1
31 pseudohermaphroditism 10.1
32 learning disability 10.1
33 radioulnar synostosis 10.1
34 microcephaly 10.0
35 lipoid congenital adrenal hyperplasia 10.0
36 oligohydramnios 10.0
37 agammaglobulinemia 10.0
38 tic disorder 10.0
39 coloboma of macula 9.9
40 elastosis perforans serpiginosa 9.9
41 nondisjunction 9.9
42 noonan syndrome 1 9.9
43 radioulnar synostosis, nonsyndromic 9.9
44 neural tube defects 9.9
45 chromosome 2q35 duplication syndrome 9.9
46 syndactyly, type iii 9.9
47 anencephaly 9.9
48 autism 9.9
49 constricting bands, congenital 9.9
50 hydrops fetalis, nonimmune 9.9

Graphical network of the top 20 diseases related to 47,xyy:



Diseases related to 47,xyy

Symptoms & Phenotypes for 47,xyy

Human phenotypes related to 47,xyy:

58 31 (show all 35)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 delayed speech and language development 58 31 hallmark (90%) Very frequent (99-80%) HP:0000750
2 low-set ears 58 31 hallmark (90%) Very frequent (99-80%) HP:0000369
3 motor delay 58 31 hallmark (90%) Very frequent (99-80%) HP:0001270
4 malar flattening 58 31 hallmark (90%) Very frequent (99-80%) HP:0000272
5 tall stature 58 31 hallmark (90%) Very frequent (99-80%) HP:0000098
6 macrocephaly 58 31 frequent (33%) Frequent (79-30%) HP:0000256
7 intellectual disability 58 31 frequent (33%) Frequent (79-30%) HP:0001249
8 hypertelorism 58 31 frequent (33%) Frequent (79-30%) HP:0000316
9 neonatal hypotonia 58 31 frequent (33%) Frequent (79-30%) HP:0001319
10 attention deficit hyperactivity disorder 58 31 frequent (33%) Frequent (79-30%) HP:0007018
11 specific learning disability 58 31 frequent (33%) Frequent (79-30%) HP:0001328
12 asthma 58 31 frequent (33%) Frequent (79-30%) HP:0002099
13 impulsivity 58 31 frequent (33%) Frequent (79-30%) HP:0100710
14 finger clinodactyly 58 31 frequent (33%) Frequent (79-30%) HP:0040019
15 impaired social interactions 58 31 frequent (33%) Frequent (79-30%) HP:0000735
16 congenital stationary night blindness 58 31 frequent (33%) Frequent (79-30%) HP:0007642
17 hydrocephalus 58 31 occasional (7.5%) Occasional (29-5%) HP:0000238
18 macroorchidism 58 31 occasional (7.5%) Occasional (29-5%) HP:0000053
19 cryptorchidism 58 31 occasional (7.5%) Occasional (29-5%) HP:0000028
20 increased circulating gonadotropin level 58 31 occasional (7.5%) Occasional (29-5%) HP:0000837
21 micropenis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000054
22 azoospermia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000027
23 hypospadias 58 31 occasional (7.5%) Occasional (29-5%) HP:0000047
24 male infertility 58 31 occasional (7.5%) Occasional (29-5%) HP:0003251
25 oligospermia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000798
26 abnormality of brainstem morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0002363
27 dysgenesis of the cerebellar vermis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002195
28 increased serum testosterone level 58 31 occasional (7.5%) Occasional (29-5%) HP:0030088
29 varicocele 58 31 occasional (7.5%) Occasional (29-5%) HP:0012871
30 cerebellar dysplasia 58 31 occasional (7.5%) Occasional (29-5%) HP:0007033
31 seizure 31 occasional (7.5%) HP:0001250
32 seizures 58 Occasional (29-5%)
33 behavioral abnormality 58 Frequent (79-30%)
34 autistic behavior 58 Occasional (29-5%)
35 hyperactivity 58 Frequent (79-30%)

GenomeRNAi Phenotypes related to 47,xyy according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 8.62 IGFBP3 SRY

Drugs & Therapeutics for 47,xyy

Drugs for 47,xyy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 163)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2
Labetalol Approved Phase 4 36894-69-6 3869
3
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
4
Cetuximab Approved Phase 4 205923-56-4 56842117 2333
5
Fluorouracil Approved Phase 4 51-21-8 3385
6
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
7
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
8
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
9 Neurotransmitter Agents Phase 4
10 Antihypertensive Agents Phase 4
11 Dermatologic Agents Phase 4
12 Adrenergic Agents Phase 4
13 Sympathomimetics Phase 4
14 Hormones Phase 4
15 Gastrointestinal Agents Phase 4
16 Psychotropic Drugs Phase 4
17 Antipsychotic Agents Phase 4
18 Anti-Anxiety Agents Phase 4
19 Trace Elements Phase 4
20 Micronutrients Phase 4
21 Adrenergic alpha-1 Receptor Antagonists Phase 4
22 Adrenergic alpha-Antagonists Phase 4
23 Adrenergic beta-Antagonists Phase 4
24 Adrenergic Antagonists Phase 4
25 Vasodilator Agents Phase 4
26 Vitamins Phase 4
27 Nutrients Phase 4
28 Calciferol Phase 4
29 Hydroxycholecalciferols Phase 4
30 Calcium, Dietary Phase 4
31 Immunosuppressive Agents Phase 4
32 Antibiotics, Antitubercular Phase 4
33 Immunologic Factors Phase 4
34 Anti-Bacterial Agents Phase 4
35 Alkylating Agents Phase 4
36 Antineoplastic Agents, Immunological Phase 4
37 Mitomycins Phase 4
38 Antimetabolites Phase 4
39
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
40
Calcium Nutraceutical Phase 4 7440-70-2 271
41
Azelaic acid Approved Phase 3 123-99-9 2266
42
Eliglustat Approved Phase 3 491833-29-5 23652731
43
Mesna Approved, Investigational Phase 3 3375-50-6 598
44
Etoposide Approved Phase 3 33419-42-0 36462
45
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
46
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
47
Lenograstim Approved, Investigational Phase 3 135968-09-1
48
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
49
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
50
Ifosfamide Approved Phase 3 3778-73-2 3690

Interventional clinical trials:

(show top 50) (show all 107)
# Name Status NCT ID Phase Drugs
1 A Phase IV Open, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of a Pediatric Presentation (0.25 ml) of the Virosomal Hepatitis A Virus (HAV) Vaccine HAVpur in Healthy Young Children Aged Between and Including 18 Months to 47 Months, Using a 0/6 Month Immunization Schedule Completed NCT01349829 Phase 4
2 Nasally Inhaled Isopropyl Alcohol Versus Oral Ondansetron for the Treatment of Nausea in the Emergency Department: A Double-Blind Randomized Controlled Trial Completed NCT02760069 Phase 4 Inhaled isopropyl alcohol;Oral ondansetron;Inhaled normal saline;Oral placebo
3 Effects of Nitroglycerin Versus Labetalol on Tissue Perfusion During Deliberate Hypotension for Sinus Endoscopic Surgery. Completed NCT03809065 Phase 4 Nitroglycerin;Labetalol
4 Vitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS Completed NCT03644212 Phase 4 Vitamin D3
5 Randomized Phase IV Trial to Compare Cetuximab With Concomitant Radiation Therapy With Concomitant Mitomycin-C and 5-Fluorouracil With Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Terminated NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
6 A Multicenter, Randomized, Controlled, Double-masked, Crossover Design Study to Compare Efficacy and Assess Safety of CD07805/47 Gel 0.5% Applied Once Daily vs Azelaic Acid Gel 15% Applied Twice Daily in Subjects With Erythema of Rosacea Completed NCT01659853 Phase 3 CD07805/47 gel 0.5%/CD07805/47 Vehicle;azelaic acid gel 15%
7 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Confirming the Efficacy and Safety of Genz-112638 in Patients With Gaucher Disease Type 1 (ENGAGE) Completed NCT00891202 Phase 3 Eliglustat tartrate;Placebo
8 Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients With High-Risk Rhabdomyosarcoma Completed NCT00354744 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate
9 A Multicenter, Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study to Demonstrate the Efficacy and Safety of CD07805/47 Gel Applied Topically Once Daily in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT01355471 Phase 3 CD07805/47 Gel;Placebo
10 A Multicenter, Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study to Demonstrate the Efficacy and Safety of CD07805/47 Gel Applied Topically Once Daily in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT01355458 Phase 3 CD07805/47 gel;Placebo
11 A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT01318733 Phase 3 CD07805/47 gel 0.5%
12 Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea Completed NCT01789775 Phase 3 Drug: CD07805/47 gel;CD07805/47 gel Placebo
13 A Phase 3, Randomized, Observer-Blind, Multicenter, Noninferiority Study to Evaluate Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) and a United States Licensed Quadrivalent Influenza Virus Vaccine (QIV) in Healthy Subjects 6 Months Through 47 Months Completed NCT04074928 Phase 3
14 A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer Completed NCT00171704 Phase 3 Letrozole;Tamoxifen
15 Randomised, Controlled Clinical Study Regarding the Feasibility of Converting Opiate Dependents From Methadone Substitutes to Slow Release Morphine Sulphate (Sevre-Long™) Completed NCT01079117 Phase 3 Sevre-Long™;Slow release oral morphine;Methadone
16 A Phase 3, Long-Term, Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects Completed NCT02610868 Phase 3 MYOBLOC
17 A Phase III, Prospective, Multicenter, Open-label Extension Study to Assess the Longer Term Safety and Efficacy of Repeated Treatment of Dysport® Intramuscular Injection in the Treatment of Cervical Dystonia Completed NCT00288509 Phase 3
18 Phase 3 Study of Vitamin D Analog (Alfacalcidol) on Muscle Strength in Elderly Indonesian Women Who Have Low Handgrip Strength Completed NCT02327091 Phase 3 alfacalcidol
19 Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis Completed NCT02207231 Phase 3 Guselkumab 100 mg;Placebo for guselkumab;Adalimumab;Placebo for adalimumab
20 A Phase 3, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus' Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to a Non-Influenza Vaccine When Administrated in Healthy Subjects Aged 6 Months Through 47 Months Recruiting NCT03932682 Phase 3
21 Effect of Adjunctive Metformin on Recurrence of Non-DM Colorectal Cancer Stage II High-risk/ III Colorectal Cancer: Open-label Randomized Controlled Recruiting NCT02614339 Phase 3 metformin;control
22 Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema Withdrawn NCT01882712 Phase 3 CD07805/47 Gel 0.5%;CD07805/47 Gel Placebo
23 The Anti-Diabetic and Cholesterol-Lowering Effects of Cinnamon and Cassia Bark (Cinnamomum Verum and C. Aromaticum) (Cinnamonforce™) - Randomized Placebo-Controlled Clinical Trial Unknown status NCT00479973 Phase 2
24 Effect of CD07805/47 Gel in Subjects Presenting With Flushing Related to Erythematotelangiectatic or Papulopustular Rosacea Completed NCT02300129 Phase 2 CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo;Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo;CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47;Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47
25 A 4-week, Randomized, Double-blind, Parallel-group, Vehicle-controlled, Multicenter Study Investigating the Efficacy and Safety of CD07805/47 Gel 0.5% Applied Topically Once Daily (QD), and CD07805/47 Gel 0.18% Applied Topically Once Daily (QD) or Twice Daily (BID), in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT01174030 Phase 2 CD07805/47 Gel;Vehicle Gel;CD07805/47 Gel;CD07805/47 Gel;Vehicle Gel
26 Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy Completed NCT01091974 Phase 2 armodafinil;Placebo Comparator
27 A Dbl-blind,Randomized,Controlled,Phase IIb Field Trial in 12-47 Month-old Children in Western Kenya to Eval the Efficacy,Safety and Immunogenicity of the FMP1/AS02A Malaria Vaccine vs Rabies Vaccine Completed NCT00223990 Phase 2
28 Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Dose-Finding Study Investigating the Pharmacodynamics and Safety of Three Concentrations of CD07805/47 Topical Gel (0.07%, 0.18%, and 0.50%), Applied in Subjects With Moderate to Severe Erythematotelangiectatic Rosacea Completed NCT00989014 Phase 2 CD07805/47;CD07805/47;CD07805/47;CD07805/47 placebo
29 Phase II Trial of Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer After Previous Local Therapy. Completed NCT00596895 Phase 2
30 A Phase II Trial to Assess the Activity of TroVax® Alone vs. TroVax® Plus Interferon Alfa (IFN-α) on Patients With Advanced or Metastatic Renal Cell Cancer Completed NCT00445523 Phase 2 Interferon-alpha
31 Double-blind, Placebo-controlled Study of Nitazoxanide Suspension in the Treatment of Rotavirus Disease in Children Completed NCT01328925 Phase 2 Nitazoxanide
32 Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC) in Patients With Metastatic or Recurrent Cancer of the Endometrium Completed NCT00249990 Phase 2 9-NC in aerosol reservoir
33 Eculizumab to Enable Renal Transplantation in Patients With History of Antiphospholipid Antibody Syndrome or Catastrophic Antiphospholipid Antibody Syndrome Completed NCT01029587 Phase 2 Eculizumab
34 Effect of Thermal Stimulation on Cortical Excitability and Motor Function in Chronic Stroke Patients Completed NCT01407536 Phase 1, Phase 2
35 Randomized Phase 2 Trial of Tirapazamine and the Role of Tumor Hypoxia in Advanced Squamous Head and Neck Cancer Completed NCT00002774 Phase 2 Tirapazamine;Cisplatin;5-fluorouracil
36 Phase II Trial of Neoadjuvant Chemoradiation With Bevacizumab for Chinese Locally Advanced Rectal Adenocarcinoma Completed NCT01554059 Phase 2 Bevacizumab;Oxaliplatin;5-FU
37 Randomized, Double-blind Placebo-controlled Multi-center Proof-of-concept Study to Assess the Efficacy of AIN457 in Patients With Psoriatic Arthritis Completed NCT00809614 Phase 2
38 Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Longkoma Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris) Implanted in Populations of 6 Weeks and Older Recruiting NCT04563533 Phase 1, Phase 2
39 Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma Recruiting NCT03047928 Phase 1, Phase 2 Nivolumab
40 Phase I/II Trial of Anti-PD-1 Checkpoint Inhibitor Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer Active, not recruiting NCT03325816 Phase 1, Phase 2 Nivolumab
41 A Pilot Study of Low Dose IL-2 in the Treatment of Relapsing Polychondritis Not yet recruiting NCT04077736 Phase 2 Interleukin-2
42 Low-dose Interleukin-2 Treatment on Polymyalgia Rheumatica Not yet recruiting NCT04062006 Phase 2 Interleukin-2
43 A Phase II Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer (47-02-001) Terminated NCT00585416 Phase 2 CGC-11047
44 IntraCoronary Treatment With Integrilin To Improve ANgiographic Outcomes (IC TITAN - TIMI 47) Trial Terminated NCT00719914 Phase 2 eptifibatide;eptifibatide;normal saline
45 Double-blind, Randomized, Placebo- and Positive-controlled, Parallel-group Trial to Assess the Potential Electrocardiographic Effects of Rotigotine Transdermal System up to 120 cm2/54.0 mg/Day in Subjects With Advanced-stage Idiopathic Parkinson's Disease: A Thorough QT/QTc Trial. Completed NCT00292227 Phase 1 Rotigotine;Moxifloxacin infusion
46 Double-blind,Randomized,Controlled,Dose Escalation Phase 1 Trial in 12-47 Month Old Children in Western Kenya to Evaluate the Safety and Immunogenicity of WRAIR's MSP-1(FMP1) Malaria Vaccine Adjuvanted in GSK's AS02A Versus Rabies Vaccine. Completed NCT00317473 Phase 1
47 A 47 Hour, Single Application, Occlusive Forearm Skin Patch Test to Assess, Under Dermatological Control, the Acute Cutaneous Tolerance of Project Storm on the Forearm of Adult Subjects With Dry/Atopic and Very Dry/Atopic Skin Completed NCT02620293 Phase 1
48 A Double-Blind, Randomized, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of V950 Formulated on Aluminum-Containing Adjuvant With or Without ISCOMATRIX™ in Patients With Alzheimer Disease Completed NCT00464334 Phase 1
49 A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignancies Recruiting NCT03717103 Phase 1 IBI188;IBI188;IBI188, Rituximab
50 A Phase 1a Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas Active, not recruiting NCT03763149 Phase 1

Search NIH Clinical Center for 47,xyy

Genetic Tests for 47,xyy

Genetic tests related to 47,xyy:

# Genetic test Affiliating Genes
1 Double Y Syndrome 29

Anatomical Context for 47,xyy

MalaCards organs/tissues related to 47,xyy:

40
Prostate, Myeloid, Bone Marrow, Endothelial, Lymph Node, Liver, Pituitary

Publications for 47,xyy

Articles related to 47,xyy:

(show top 50) (show all 30000)
# Title Authors PMID Year
1
Clinical aspects of infertile 47,XYY patients: a retrospective study. 61 20
28715980 2019
2
Oral, physical, and behavioral aspects of patient with chromosome 47, XYY syndrome. 20 61
26381641 2015
3
Positive effects of early androgen therapy on the behavioral phenotype of boys with 47,XXY. 61 20
25939399 2015
4
Clinical profile of a Polish cohort of children and young adults with cystinuria. 61
33349102 2021
5
Validity of Tools to Measure Physical Activity in Older Adults Following Total Knee Arthroplasty. 61
33378742 2021
6
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. 61
33220855 2021
7
Filamentous fungi occurrence on Molossus molossus (Pallas, 1766) (Chiroptera: Molossidae) present in an Atlantic Forest remnant in Southern Brazil. 61
33053139 2021
8
Improved hemostatic effects by Fe3+ modified biomimetic PLLA cotton-like mat via sodium alginate grafted with dopamine. 61
33553820 2021
9
The effects of blanching on composition and modification of proteins in navy beans (Phaseolus vulgaris). 61
33465570 2021
10
Emotional working memory updating in individuals with borderline personality features. 61
33476888 2021
11
Ultrasound processing of rutin in food-grade solvents: Derivative compounds, antioxidant activities and optical rotation. 61
33272752 2021
12
Ultrasound-assisted modification of rutin to nanocrystals and its application in barley starch pyrodextrinization. 61
33243560 2021
13
Magnetic seeding coagulation: Effect of Al species and magnetic particles on coagulation efficiency, residual Al, and floc properties. 61
33360935 2021
14
A DNA methylation panel for high performance detection of colorectal cancer. 61
33387936 2021
15
Hair endocannabinoid concentrations in individuals with acute and weight-recovered anorexia nervosa. 61
33444649 2021
16
Perinatal exposure to BDE-47 exacerbated autistic-like behaviors and impairments of dendritic development in a valproic acid-induced rat model of autism. 61
33550075 2021
17
MRI-histopathological correlation in paediatric conventional central chondrosarcoma: a report of 17 cases. 61
32959335 2021
18
Interventional radiology procedural volume changes during COVID-19 initial phase: A tertiary level Midwest health system experience. 61
33202292 2021
19
Interspecies comparisons of brominated flame retardants in relation to foraging ecology and behaviour of gulls frequenting a UK landfill. 61
33131861 2021
20
Trace Elements in Breakfast Cereals and Exposure Assessment in Moroccan Population: Case of Lead and Cadmium. 61
32578138 2021
21
Improve Bystander Cardiopulmonary Resuscitation in the Chinese Community. 61
32631151 2021
22
Long non‑coding RNA KCNQ1OT1 promotes nasopharyngeal carcinoma cell cisplatin resistance via the miR‑454/USP47 axis. 61
33576460 2021
23
Older adults with SARS-CoV-2 infection: Utility of the clinical frailty scale to predict mortality. 61
33377529 2021
24
Value of dynamic contrast-enhanced magnetic resonance imaging for determining the plasma Epstein-Barr virus status and staging of nasopharyngeal carcinoma. 61
33190027 2021
25
Prenatal exposure to a wide range of environmental chemicals and child behaviour between 3 and 7 years of age - An exposome-based approach in 5 European cohorts. 61
33422710 2021
26
Two-stage hybrid constructed wetland-microbial fuel cells for swine wastewater treatment and bioenergy generation. 61
33143898 2021
27
Evaluation of a characterization method of Egyptian human mummy balms by chemometric treatments of infrared data. 61
33592704 2021
28
Cross-linked bionanocomposites of hydrolyzed guar gum/magnetic layered double hydroxide as an effective sorbent for methylene blue removal. 61
33541654 2021
29
Professional patient navigation in a hospital setting: a randomized controlled trial. 61
32864723 2021
30
Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. 61
33544838 2021
31
Cerebral toxoplasmosis with multiple hemorrhage lesions in an HIV infected patient: A case report and literature review. 61
33401016 2021
32
Toxicity and accumulation of 6-OH-BDE-47 and newly synthesized 6,6'-diOH-BDE-47 in early life-stages of Zebrafish (Danio rerio). 61
33131876 2021
33
CACNA1B gene variants in adult-onset isolated focal dystonia. 61
33051750 2021
34
The prevalence of small-bowel polyps on video capsule endoscopy in patients with sporadic duodenal or ampullary adenomas. 61
32717365 2021
35
Decreased Expression of Heat Shock Protein 47 Is Associated with T-2 Toxin and Low Selenium-Induced Matrix Degradation in Cartilages of Kashin-Beck Disease. 61
32591934 2021
36
Two-step Testing for Clostridioides Difficile is Inadequate in Differentiating Infection From Colonization in Children. 61
32925555 2021
37
Evaluation of SWI/SNF Protein Expression by Immunohistochemistry in Ovarian Clear Cell Carcinoma. 61
32897960 2021
38
Trends in delayed breast cancer diagnosis after recall at screening mammography. 61
33421886 2021
39
Glycaemic efficacy and safety of mealtime faster-acting insulin aspart administered by injection as compared to insulin aspart in people with diabetes mellitus: A meta-analysis of randomized controlled trials. 61
33420727 2021
40
The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes. 61
33269512 2021
41
Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy. 61
32530363 2021
42
Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer. 61
33485662 2021
43
Inhibition of the mevalonate pathway improves myocardial fibrosis. 61
33603833 2021
44
Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma. 61
32265358 2021
45
Role of aging and working memory in performance on a naturalistic visual search task. 61
33453649 2021
46
Pharmacists experience of and perspectives about recruiting patients into a community pharmacy asthma service trial. 61
32448767 2021
47
A life course approach to elucidate the role of adiposity in asthma risk: evidence from a Mendelian randomisation study. 61
33051271 2021
48
Intravenous paracetamol for neonates: long-term diseases not escalated during 5 years of follow-up. 61
32943529 2021
49
Excess mortality in England and Wales during the first wave of the COVID-19 pandemic. 61
33060194 2021
50
Therapeutic plasma exchange: single-center experience in children with kidney disorders. 61
32949283 2021

Variations for 47,xyy

Expression for 47,xyy

Search GEO for disease gene expression data for 47,xyy.

Pathways for 47,xyy

GO Terms for 47,xyy

Sources for 47,xyy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....